TL;DR:
- Tempus announces the broad launch of Tempus One, an AI-enabled clinical assistant.
- Tempus One provides clinicians with quick access to patient insights through voice and text assistance.
- It offers comprehensive clinical and molecular profiles, along with various datasets for real-time clinical decisions.
- Tempus One allows clinicians to access test reports, filter patient incidence, review biomarkers, and query clinical guidelines.
- The technology has been refined based on physician feedback and is built on generative AI and large language models.
- Tempus leverages its vast healthcare dataset and aims to improve treatment decisions for clinicians.
Main AI News:
Tempus, a trailblazer in the realm of artificial intelligence (AI) and precision medicine, has made a groundbreaking announcement today regarding the highly anticipated broad launch of Tempus One. This innovative platform marks a significant milestone in the healthcare industry as the first AI-enabled clinical assistant that seamlessly integrates generative AI advancements to empower clinicians with instant access to vital patient insights.
Tempus One, available as a voice and text assistant through the Tempus Hub desktop and mobile app, has been thoughtfully designed to equip clinicians with swift access to comprehensive clinical and molecular profiles of their patients. Moreover, it offers an array of diverse datasets that can be conveniently queried by physicians to facilitate real-time clinical decision-making. The capabilities of Tempus One are extensive, enabling clinicians to effortlessly access new clinical test reports, receive timely status updates on patient reports, filter patient incidence based on alterations, genes, or diagnoses, obtain concise summaries of patient information, review report details on actionable biomarkers, and effortlessly access up-to-date clinical guidelines for the highest standard of care insights.
Having initially introduced the prototype of Tempus One in early 2021, Tempus has been an early adopter of generative AI. To refine and enhance this groundbreaking technology, the company enrolled a cohort of clinicians into a pilot program, granting them the role of provisional beta users. Valuable feedback from these users indicated a preference for employing the Tempus One technology on their existing devices, such as desktops and mobile apps, as opposed to the initial cube prototype. Armed with this insight, Tempus dedicated the past two years to refining Tempus One, incorporating generative AI into the clinical care setting by building it atop extensive language models. This meticulous approach, driven by physician feedback and thorough user testing, has paved the way for a broader commercial launch of Tempus One.
Eric Lefkofsky, the visionary Founder and CEO of Tempus, expressed his enthusiasm for this game-changing technology, saying, “Tempus One leverages our vast healthcare dataset, which now exceeds 100 petabytes of curated data, and uses pioneering advancements in generative AI, enabling us to place our precision medicine platform at the fingertips of every clinician we serve, ultimately improving their ability to make data-driven treatment decisions on behalf of their patients.”
Dr. Sandip Patel of UC San Diego Health, an esteemed expert in the field, further emphasized the significance of assistive technologies like Tempus One, stating, “Tempus One demonstrates the power of assistive technologies by simplifying the often complex process of ordering, obtaining, and interpreting genomic testing. The ability to have a voice assistant augment our efforts in delivering precision oncology allows us to unlock the power of artificial intelligence for direct clinical benefit for our patients.”
Conclusion:
The launch of Tempus One marks a significant advancement in the healthcare market. By incorporating AI and generative AI technologies, Tempus empowers clinicians with a powerful tool to access critical patient insights in real-time. This not only streamlines the decision-making process but also enhances precision medicine by enabling data-driven treatment decisions. With its broad commercial launch, Tempus is set to reshape the market by placing its precision medicine platform directly into the hands of clinicians, ultimately improving patient care and outcomes. The integration of AI in clinical care settings represents a major shift in the industry, highlighting the potential for assistive technologies to revolutionize healthcare delivery.
